The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
Open accessAbstract
BACKGROUND: Preclinical data have shown that proton pump inhibitors (PPI) can modulate the microbiome, and single-arm studies suggested that antibiotics (ATB) may decrease the efficacy of immune checkpoint inhibitors (ICI), but randomized controlled trial data are lacking. This pooled analysis evaluated the effect of ATB and PPI on outcome in patients randomized between ICI and chemotherapy. PATIENTS AND METHODS: This retrospective analysis used pooled data from the phase II POPLAR (NCT01903993) and phase III OAK (NCT02008227) trials, which included 1512 patients with previously treated non-small-cell lung cancer (NSCLC) randomly assigned to receive atezolizumab (n = 757) or docetaxel (n = 755). The main objective of this analysis was to assess the impact of ATB and PPI use on overall survival (OS) and progression-free survival (PFS). RESULTS: A total of 169 (22.3%) patients in the atezolizumab group and 202 (26.8%) in the docetaxel group received ATB, and 234 (30.9%) and 260 (34.4%), respectively, received PPI. Multivariate analysis in all patients revealed that ATB were associated with shorter OS [hazard ratio (HR) 1.20, 95% confidence interval (CI) 1.04-1.39], as was PPI (HR 1.26, 95% CI 1.10-1.44). Within the atezolizumab population, OS was significantly shorter in patients who received ATB (8.5 versus 14.1 months, HR 1.32, 95% CI 1.06-1.63, P = 0.01) or PPI (9.6 versus 14.5 months, HR 1.45, 95% CI 1.20-1.75, P = 0.0001). PPI use was associated with shorter PFS in the atezolizumab population (1.9 versus 2.8 months, HR 1.30, 95% CI 1.10-1.53, P = 0.001). There was no association between ATB and PPI use and PFS or OS within the docetaxel population. CONCLUSION: In this unplanned analysis from two randomized trials, data suggest that ATB or PPI use in patients with metastatic NSCLC is associated with poor outcome and may influence the efficacy of ICI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have demonstrated associations between microbiota composition and response to ICB in cancer patients, and evidence suggests that use of antibiotics near the start of treatment can alter therapy efficacy (Chalabi et al., 2020; Chaput et al., 2017; Frankel et al., 2017; Gopalakrishnan et al., 2018; Khan et al., 2021; Matson et al., 2018; Pinato et al., 2019; Routy et al., 2018).”
From Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment (2021) · cites this paper as Chalabi et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citationMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–292 of 292
First-line immunotherapy in non-small cell lung cancer: how to select and where to go
Mogavero, A., Cantale, O., Mollica, V., Anpalakhan, S., Addeo, A., Mountzios, G., Friedlaender, A., Kanesvaran, R., Novello, S., & Banna, G. L. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2302356 · Cited by 5
Uhlenbruch, M., & Krüger, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05916-x · Cited by 4
Coniac, S., Costache-Outas, M. C., Antone-Iordache, I.-L., Barbu, A.-M., Bardan, V. T., Zamfir, A., Ionescu, A.-I., & Badiu, C. (2025) · Cancers · doi:10.3390/cancers17071198 · Cited by 4
Tsuboi, I., Matsukawa, A., Parizi, M. K., Miszczyk, M., Fazekas, T., Schulz, R. J., Laukhtina, E., Kawada, T., Katayama, S., Iwata, T., et al. (2025) · BMC Urology · doi:10.1186/s12894-025-01754-2 · Cited by 4
Hata, T., Yamada, T., Gotô, Y., Amano, A., Negi, Y., Watanabe, S., Furuya, N., Oba, T., Ikoma, T., Nakao, A., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0157 · Cited by 4
Uhlenbruch, M., & Krüger, S. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03734-z · Cited by 4
Tsuboi, I., Matsukawa, A., Parizi, M. K., Miszczyk, M., Fazekas, T., Schulz, R. J., Mancon, S., Litterio, G., Laukhtina, E., Kawada, T., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102237 · Cited by 4
Wu, B., Sun, C. M., Sun, X., & Li, X. (2022) · Medicine · doi:10.1097/md.0000000000030532 · Cited by 4
Perret, M., Bertaut, A., Niogret, J., Marilier, S., Jouanny, P., Manckoundia, P., Bengrine-Lefèvre, L., Quipourt, V., & Barben, J. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01048-y · Cited by 4
Predicting drug outcome of population via clinical knowledge graphPreprint
Brbić, M., Yasunaga, M., Agarwal, P., & Leskovec, J. (2024) · medRxiv · doi:10.1101/2024.03.06.24303800 · Cited by 6
Russi, A., Saran, C., Zanchetta, G., Zorzetto, G., Crivellaro, G., Maruzzo, M., Pasello, G., Fabozzi, A., Toni, C. D., Cenzi, C., et al. (2025) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/5572209 · Cited by 3
Takagaki, K., Ohno, Y., Otsuki, T., Kubota, A., Kijima, T., & Tanaka, T. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70081 · Cited by 3
Morikawa, N., Naito, T., Morita, M., Sekikawa, M., Doshita, K., Yabe, M., Kodama, H., Miura, K., Iida, Y., Mamesaya, N., et al. (2024) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2024.101832 · Cited by 3
Götz, L., Ansafi, T., Gerken, M., Klinkhammer‐Schalke, M., Fischl, A., Riemenschneider, M. J., Proescholdt, M. A., Bumes, E., Kölbl, O., Schmidt, N. O., et al. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae170 · Cited by 3
Deng, H., Zhou, J., Liu, Z., Huang, L., Gu, Y., Chen, P., & Xiao, H. (2025) · Medical Oncology · doi:10.1007/s12032-024-02591-3 · Cited by 3
Zhou, J., You, D., Chen, M., Chen, X., Wang, S., Peng, B., Lange, T., Ma, H., Shen, H., Chen, F., et al. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100124 · Cited by 3
Yamaguchi, M., Kawazoe, H., Kasai, Y., Hirata, K., & Ohtani, H. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01354-1 · Cited by 3
Cao, X., Wang, Y., Huang, W., Li, P., Guo, C., & Li, Y. (2023) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000991 · Cited by 3
Nasu, I., Kondo, M., Uozumi, R., Takada, S., Nawata, S., Iihara, H., Okumura, Y., Takemoto, M., Mino, K., Sasaki, T., et al. (2023) · Journal of Cancer · doi:10.7150/jca.80517 · Cited by 3
SUrvey of renal Biopsy registry database and Anticancer dRUg therapy in Japan (SUBARU-J study)
Kuwabara, T., Miyasato, Y., Kanki, T., Mizumoto, T., Matsubara, T., Sawa, N., Sugiyama, H., Maruyama, S., Sato, H., Tsukamoto, T., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae327 · Cited by 3
Zheng, J., Cui, T., Gao, Y., & Li, T. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221091540 · Cited by 3
Kwon, M. J., Kang, H. S., Choi, H. G., Kim, J. H., Kim, J. H., Bang, W., Yoo, D. M., Lee, N.-E., Han, K. M., Kim, N. Y., et al. (2025) · Cancers · doi:10.3390/cancers17050877 · Cited by 2
Coniac, S., Costache-Outas, M. C., Antone-Iordache, I.-L., Anghel, A.-V., Bobolocu, M.-A., Zamfir, A., Lișcu, H.-D., Ionescu, A.-I., & Badiu, C. (2025) · Current Oncology · doi:10.3390/curroncol32060332 · Cited by 2
Takada, K., Shimokawa, M., Cortellini, A., Pinato, D. J., Mizuki, F., & Takamori, S. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108787 · Cited by 3
Su, P., Tao, Y., Wang, A., & Xiao, Y. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004476 · Cited by 3
Japelj, N., Horvat, N., Jazbar, J., Kerec Kos, M., Pelicon, V., & Knez, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1682723 · Cited by 2
Miyamoto, I., Shimizu, T., Hanamura, M., Tanaka, R., Kusahana, R., Nomoto, M., Sugaya, K., Nakagawa, Y., & Gon, Y. (2026) · BMC Cancer · doi:10.1186/s12885-026-15646-7 · Cited by 2
Petouhoff, A., Hicks, R., Husain, M., Hoyd, R., Xu, M., Dravillas, C. E., Patel, S. H., Johns, A. C., Grogan, M. M., Li, M., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04346-7 · Cited by 2
A New Antiport Mechanism Using the Abnormal Adsorption of Ions
Liu, Y. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c02110 · Cited by 2
Yu, Z., Li, Q., & Yu, G. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100758 · Cited by 2
Lee, H.-S., Wei, Y., & Shu, C. (2023) · Biomedicines · doi:10.3390/biomedicines11123130 · Cited by 2
Gao, L., Liu, Y., Liu, J., Li, J., Li, H., Liu, Y., Meng, F., Du, X., Gao, Y., Li, J., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7083 · Cited by 2
Isono, T., Furuno, H., Onodera, Y., Maruyama, T., Takeuchi, Y., Kojima, A., Nishida, T., Kobayashi, Y., Ishiguro, T., Takaku, Y., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.08.013 · Cited by 2
Deng, F., Ye, H., Zhang, P., Xu, J., Li, Y., Sun, M., & Yang, Z. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15492 · Cited by 2
Quaquarini, E., Sottotetti, F., Agustoni, F., Pozzi, E., Malovini, A. L., Teragni, C. M., Palumbo, R., Saltalamacchia, G., Tagliaferri, B., Balletti, E., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050679 · Cited by 2
FAIT CLINIQUE À PROPOS D'UN CAS DE PANCRÉATITE AIGUË RÉVÉLANT UNE DILATATION KYSTIQUE DU CHOLÉDOQUE
Kabbaj, N., Ababou, A., Fakir, Y. E., Amarouch, N., Dafiri, R., & Imani, A. S. E. F. (2008) · Cited by 2
Sekito, T., Bekku, K., Katayama, S., Watanabe, T., Tsuboi, I., Yoshinaga, K., Maruyama, Y., Yamanoi, T., Kawada, T., Tominaga, Y., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102097 · Cited by 2
Zheng, L., Yang, J., Chen, X., Li, L., & Sun, J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231163807 · Cited by 1
Hori, T., Yamamoto, K., Ito, T., Ikushima, S., Omura, T., & Yano, I. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02859-2 · Cited by 1
Modi, N. D., Abuhelwa, A. Y., Kuderer, N. M., Li, L. X., Lyman, G. H., Koczwara, B., Kichenadasse, G., Selth, L. A., Rickard, C., Haseloff, M., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71320 · Cited by 1
Li, L. X., Hopkins, A. M., Woodman, R. J., Abuhelwa, A. Y., Gao, Y., Parent, N., Rowland, A., & Sorich, M. J. (2025) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2025.112082 · Cited by 1
Microbiome‐urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation
Xu, H., Li, Z., Yang, L., Zheng, J., Li, W., Liao, R., Huang, W., Sun, B., Li, Z., Ma, C., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70081 · Cited by 1
Microbiota as a modulator of drug response: targeting microbial–drug crosstalk in cancer therapy
Zhao, T., Liu, M., Qiu, L. X., Zhang, H., Zhang, N., Liu, Z., Xia, Z., Luo, P., Huang, J., & Cheng, Q. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2651930 · Cited by 1
Fujimoto, A., Uozumi, R., Fujii, H., Tamaki, S., Eto, T., Yamaguchi, M., Maehara, Y., Iihara, H., HATAKEYAMA, T., Higuchi, A., et al. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01499-7 · Cited by 1
Sugimoto, K., Toyoda, S., Inoki, L., Mori, K., Yanagisawa, T., Tamura, K., Nukaya, T., Maenosono, R., Morinaka, H., Nishimura, S., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03075-2 · Cited by 1
Microbiome as a prediction of immunotherapy response in lung cancer
Rojas, L., Zuluaga, J., & Cardona, A. F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1849553 · Cited by 1
Self-citationPredictive Factors for the Efficacy of Immune Checkpoint Inhibitors Against Lung Cancer
Ochi, N., Yamane, H., & Takigawa, N. (2022) · Haigan · doi:10.2482/haigan.62.355 · Cited by 1
Veremme, L., Baudouin, A., Janoly-Duménil, A., & Charpiat, B. (2022) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2022.11.006 · Cited by 1
The Effects of Antibiotics on the Development and Treatment of Non-Small Cell Lung Cancer
Švecová, P., Jakubec, P., Škarda, J., Glogarová, V., & Mitták, M. (2023) · Polish Journal of Microbiology · doi:10.33073/pjm-2023-047 · Cited by 1
IMMUNOLOGICAL COMPOUNDS FOR CANCER THERAPY
Garg, R. (2024) · doi:10.59551/ijhmp/25832069/2024.5.1.50 · Cited by 1
Kaneko, T., Doki, K., Yamada, T., Uda, M., Yamamoto, Y., Kobayashi, M., Tsuchiya, K., & Homma, M. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70202 · Cited by 1
Medication and Health Risks Associated With Neglected Side Effects on Gut Microbiota
Velikova, T. V., Nakov, R., & Ianiro, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00074-7 · Cited by 1
Funada, S., Yoshioka, T., & Luo, Y. (2020) · European Urology · doi:10.1016/j.eururo.2020.09.008 · Cited by 1
Mao, H., Tong, J., Yan, X., Liu, C., Yang, M., & Guo, H. (2021) · Research Square · doi:10.21203/rs.3.rs-622772/v1 · Cited by 1
The deleterious effect of acetaminophen in cancer immunotherapy
Berraondo, P., & Sullivan, R. J. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.012 · Cited by 1
Bidirectional interactions of gut microbiome and medicinal products
Ткач, С. М. (2020) · Modern Gastroenterology · doi:10.30978/mg-2020-5-79 · Cited by 1
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
Davies, M. J., & Russo, A. V. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_7
Wu, C., Ke, Y., Wan, L., & Xie, X. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3982290
Wechselwirkungen mit Chemotherapie?
(2022) · Deutsche Zeitschrift für Onkologie · doi:10.1055/a-1701-2124
Cao, X., yafei, W., wei, H., Li, P., chongjie, G., & Li, Y. (2022) · doi:10.22541/au.165090979.95584138/v1
Wang, M., Lu, D., & Bi, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108955
Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges
Hosseini, M., & Rezaei, N. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_52
Mechanisms of Resistance to Immunotherapies in Cancer
Lengyel, C. G. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_335-1
Lung Immunotherapy in the Elderly with NSCLC – the Who, the What, and the When
Alexa‐Stratulat, T., Marinca, M. V., Alexa, I.-D., & Antoniu, S. A. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_119
Köster, W., & Scheffer, C. (2023) · Der Merkurstab · doi:10.14271/dms-21613-de
Influence of Antibiotic Use on the Effectiveness and Safety of Immune Checkpoint Inhibitors
Minamishima, T., Hida, H., Miyazaki, M., Kon, S., Senzaki, K., Nagai, T., & Yamada, K. (2022) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.48.173
Argoubi, R., Reese, E. S., Furegato, M., Medina, P., & Bobiak, S. N. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2022-0201
The Potential of CD4+ T cells ATP level to indicate the Progression in NSCLC PatientsPreprint
Ye, W., Hou, K., tao, N., Li, W., Tan, Z., Huang, Q., yang, D., Lin, H., Deng, Z., Xia, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3737437/v1
Wan, N., Chen, Y., Lu, L., Wang, B., He, L., Liang, H., Xie, F., Jian, X., Ji, B., & Zhang, J. (2024) · European Journal of Cancer Care · doi:10.1155/2024/6004679
Yan, Y., Rong, S., Xi, Y., Peng, H., Wang, X., Wang, X., Wu, X., Zhu, T., Wu, G., Yu, M., et al. (2024) · Clinical Cancer Bulletin · doi:10.1007/s44272-024-00014-y
Ye, W., Hou, K., Tao, N., Li, W., Tan, Z., Huang, Q., yang, D., Lin, H., Deng, Z., Xia, Y., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14502
Kikuta, S., Hattori, C., Abe, Y., Hino, K., Matsuo, K., & Kusukawa, J. (2025) · Oral Diseases · doi:10.1111/odi.70051
Qu, Z., Wang, Y., Wang, Z., Zhang, Y., Zhang, Y., & Gu, K. (2025) · Discover Oncology · doi:10.1007/s12672-025-03558-0
Mechanisms of Resistance to Immunotherapies in Cancer
Lengyel, C. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-00775-9_335
Ye, Q., Liu, M., Xu, M., Cui, M., & Yan, B. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110543
Microflora: a promising potential in the diagnosis and treatment of non-small cell lung cancer
Wang, L., Chi, Y., Min, Z., Jiang, J., Meng, Z., & Wang, Z. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02934-8
Morandi, S. C., Herzog, E. L., Munk, M., Kreuzer, M., Largiadèr, C. R., Wolf, S., Zinkernagel, M. S., & Zysset‐Burri, D. C. (2024) · Figshare · doi:10.6084/m9.figshare.25770398
Takada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., Otsubo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19728038
Takada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., Otsubo, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19728041
Zhang, S., Tian, J., Wang, X., & Liu, C. (2024) · Figshare · doi:10.6084/m9.figshare.26638644
Zhang, S., Tian, J., Wang, X., & Liu, C. (2024) · Figshare · doi:10.6084/m9.figshare.26638647
Takada, K., Cortellini, A., Takamori, S., Mizuki, F., Pinato, D. J., & Shimokawa, M. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70300
Crosstalk Between Opioids and the Anti-Tumour Immune Checkpoint Axis
Alan, P., & Parat, M. (2026) · Current Oncology · doi:10.3390/curroncol33070411
Zhai, Z., Ma, S., Shang, S., Liang, X., Yin, S., Lin, H., Ding, R., Jiang, A., Zhang, R., Wu, M., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag264 · Cited by 1
Coniac, S., Ionescu, R. T., Costache-Outas, M. C., Antone-Iordache, I.-L., Barbu, A.-M., Bardan, V. T., Zamfir, A., Ionescu, A. O., & Badiu, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-48803-w
Yamaguchi, M., Uozumi, R., Eto, T., Fujimoto, A., Iihara, H., HATAKEYAMA, T., Higuchi, A., Maehara, Y., Fujii, H., Tamaki, S., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117014
Ihara, Y., Okada, N., Mizutani, M., Nakamura, Y., Shimomura, Y., & YAMAMOTO, S. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70478
Sonji, G. M., Sonji, N. M., & Katerji, A. E. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04963-0
Vattaire-Hervé, M., Barbe, C., Bouazzi, L., & Parent, D. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261496825
Xu, Z., Wu, X., 林敏美, & 叶林淼 (2026) · Research Square · doi:10.21203/rs.3.rs-10912025/v1
Wu, Y., & Fan, W. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105654
Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications
Porcari, S., Bolte, L. A., Björk, J. R., Elkrief, A., Derosa, L., Ferrari, M., Pezzullo, A. M., Severino, A., Fusco, W. G., Messaoudene, M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.012
Metadata
- Authors
- Chalabi, M., Cardona, A., Nagarkar, D. R., Dhawahir Scala, A., Gandara, D. R., Rittmeyer, A., Albert, M. L., Powles, T., Kok, M., & Herrera, F. G.
- Affiliations
- The Netherlands Cancer Institute (NL)
- F. Hoffmann-La Roche AG (CH)
- Genentech (US)
- UC Davis Comprehensive Cancer Center (US)
- Barts Cancer Institute (GB)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Chalabi, M.
- Herrera, F.G.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 31
- Issue
- 4
- Pages
- 525-531
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3000696551
- Semantic Scholar
- 1d776be113ebef731e6a54113731c7db0cd5ccf0
- Cited by
- 294
- References
- 24
- Citations by year
- 2026: 22 · 2025: 40 · 2024: 42 · 2023: 44 · 2022: 60 · 2021: 55 · 2020: 29
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- IRIS (submittedVersion, cc-by-nc-nd)
- SERVAL (Université de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- F. Hoffmann-La Roche Ltd
- F Hoffmann-La Roche
- Genentech
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- non-small cell lung cancer, atezolizumab, proton pump inhibitors, antibiotics, immune checkpoint inhibitors, chemotherapy, docetaxel, microbiome, overall survival, progression-free survival, OAK trial, POPLAR trial, drug interactions, immunotherapy efficacy, previously treated patients, PD-L1 expression, PD-1 expression, PD-1/PD-L1 blockade
- MeSH terms
- Anti-Bacterial Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Retrospective Studies, Proton Pump Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
